PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation.
Autosomal dominant polycystic liver disease (PCLD) is caused by mutations of either PRKCSH or Sec63, two proteins associated with the endoplasmic reticulum (ER). Both proteins are involved in carbohydrate processing, folding and translocation of newly synthesized glycoproteins. It is postulated that defective quality control of proteins initiates endoplasmic reticulum-associated degradation (ERAD), which disrupts hepatic homeostasis in patients with PRKCSH or Sec63 mutations. However, the precise molecular mechanisms are not known. Here, we show that over-expression or depletion of PRKCSH in zebrafish embryos leads to pronephric cysts, abnormal body curvature and situs inversus. Identical phenotypic changes are induced by depletion or over-expression of TRPP2. Increased PRKCSH levels ameliorate developmental abnormalities caused by over-expressed TRPP2, whereas excess TRPP2 can compensate the loss PRKCSH, indicating that the proteins share a common signaling pathway. PRKCSH binds the C-terminal domain of TRPP2, and both proteins co-localize within the ER. Furthermore, PRKCSH interacts with Herp, and inhibits Herp-mediated ubiquitination of TRPP2. Our findings suggest that PRKCSH functions as a chaperone-like molecule, which prevents ERAD of TRPP2. Dysequilibrium between TRPP2 and PRKCSH may lead to cyst formation in PCLD patients with PRKCSH mutations, and thereby account for the overlapping manifestations observed in PCLD and autosomal dominant polycystic kidney disease.
Gao
Hongyu
H
Renal Division, University Hospital Freiburg, Freiburg, Germany.
Wang
Yan
Y
Wegierski
Tomasz
T
Skouloudaki
Kassiani
K
Pütz
Michael
M
Fu
Xiao
X
Engel
Christina
C
Boehlke
Christopher
C
Peng
Hongquan
H
Kuehn
E Wolfgang
EW
Kim
Emily
E
Kramer-Zucker
Albrecht
A
Walz
Gerd
G
D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D004285:Dogs; D004625:Embryo, Nonmammalian / Q000002:abnormalities / Q000187:drug effects; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D055785:Gene Knockdown Techniques; D006801:Humans; D018832:Molecular Chaperones / Q000235:genetics / Q000378:metabolism*; D009154:Mutation / Q000235:genetics*; D009399:Nephrons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D016891:Polycystic Kidney, Autosomal Dominant / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D050396:TRPP Cation Channels / Q000235:genetics / Q000378:metabolism*; D054875:Ubiquitination / Q000187:drug effects; D014452:Ubiquitins / Q000235:genetics / Q000378:metabolism*; D015027:Zebrafish / Q000196:embryology; D029961:Zebrafish Proteins / Q000235:genetics / Q000378:metabolism*
D002352:Carrier Proteins; D018832:Molecular Chaperones; D016376:Oligonucleotides, Antisense; D050396:TRPP Cation Channels; D014452:Ubiquitins; D029961:Zebrafish Proteins; C547527:PKD2 protein, zebrafish; C547526:PRKCSH protein, zebrafish